Recursion Pharmaceuticals (RXRX) said Sunday early results from a phase 1/2 trial of its drug REC-4881 for Familial Adenomatous Polyposis showed a median reduction in polyp burden of 43% after 13 weeks among six patients who were evaluated.
The company said five patients saw polyp reductions between 31% and 82%, while one experienced a sharp increase compared to 20% to 30% reductions in other drugs over six months.
Three patients also showed improvement in the Spigelman stage, while one worsened and two had mixed or unclear results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.